To include your compound in the COVID-19 Resource Center, submit it here.

Sutro, Celgene revamping immuno-oncology deal

Sutro Biopharma Inc. (South San Francisco, Calif.) said it is refocusing a 2014 immuno-oncology multi-specific antibody and antibody-drug conjugate (ADC) deal with Celgene Corp. (NASDAQ:CELG). As part of the new agreement, the partners terminated Celgene's option to acquire Sutro.

In the original 2014 deal, the

Read the full 446 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE